

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Zeldis	Confirmation No.:	1866
Serial No.:	10/699,110	Art Unit:	1612
Filed:	October 30, 2003	Examiner:	Fay, Zohreh A.
For:	Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration	Attorney Docket No:	9516-083-999
		CAM:	501872-999082

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


Pursuant to Applicant's duty of disclosure under 37 C.F.R. § 1.56, enclosed is a list references for the Examiner's review and consideration. The references are listed on the enclosed "List of References Cited by Applicant." Copies of reference B01 and C01-C02 are submitted herewith.

Identification of the foregoing reference is not to be construed as an admission of Applicant or Attorneys for Applicant that such reference is available as "prior art" against the subject application. Applicant respectfully requests that the Examiner review the reference and make it of record by completing and returning the enclosed List of References.

A fee of \$180.00 is believed due for the submission of this Supplemental Information Disclosure Statement. This fee is paid concurrently herewith via EFS. If any additional fees are required, the Director is authorized to charge such fees to Jones Day Deposit Account No. 503013.

Respectfully submitted,

Date: October 9, 2009


Robert Chang Reg. No.: 63,753
for: Anthony M. Insogna Reg. No.: 35,203

JONES DAY
222 East 41st Street
New York, NY 10017
(858) 314-1200